Sujit Basu

ORCID: 0000-0002-8272-0807 · 3 papers in corpus
other 2026
Beyond inhibition: harnessing the DRD2-VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer
Frontiers in oncology ·doi:10.3389/fonc.2026.1818655

Current anti-angiogenic therapies using vascular endothelial growth factor-A/vascular endothelial growth factor receptor-2 (VEGF-A/VEGFR2) inhibitors lack dynamic biomarkers that can facilitate patient selection and optimize dosing; this ca…

review 2026
Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities
FASEB journal : official publication of the Federation of American Societies for Experimental Biology ·doi:10.1096/fj.202600843R

Angiogenesis mediated by vascular endothelial growth factor A (VEGF-A) is essential for physiological vascular remodeling but also drives pathological processes, including tumor growth, ocular neovascularization, and inflammation. Emerging …

lab-animal 2022
VEGF-A controls the expression of its regulator of angiogenic functions, dopamine D2 receptor, on endothelial cells
Journal of cell science ·doi:10.1242/jcs.259617

We have previously demonstrated significant upregulation of dopamine D2 (DAD2) receptor (DRD2) expression on tumor endothelial cells. The dopamine D2 receptors, upon activation, inhibit the proangiogenic actions of vascular endothelial grow…